|Pre-clinical||Phase 1||Phase 2||Phase 3|
IBD (UC and Crohn’s)
|Inflammation and Fibrosis||
|FXR NASH||Ph 1|
|FXR IBD (UC and Chron’s)||Ph 1|
|FXR IBS-D||Ph 1|
We have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design drugs with characteristics that we view as key to safety and efficacy.
With this systematic approach, we have designed novel farnesoid X receptor (FXR) agonists and have identified a potential role for them in the treatment of non-alcoholic steatohepatitis (NASH), inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn’s disease (Crohn’s), and irritable bowel syndrome with diarrhea (IBS-D). Beyond our FXR program, we are building a pipeline of novel drug candidates by taking advantage of our drug discovery and development capabilities.
Step 1 of 4
The FXR drug (agonist) is taken orally and travels through the stomach to the intestine. In the intestine the FXR agonist binds to and activates the FXR receptor.
Step 2 of 4
FXR receptor activation causes cells in the intestine to release a protein called FGF19 which travels to the liver
Step 3 of 4
Once in the liver FGF19, binds to its receptor and causes a decrease in the synthesis of bile acids.
Step 4 of 4
In addition to the intestine, the FXR agonist also activates FXR receptors in the liver which can provide additional regulation of bile acid synthesis and maintenance of the bile acid pool.
We have purposefully designed compounds to be non-bile acids, with sustained FXR engagement and high potency, dosed orally, once-a-day. With this profile, we believe our FXR agonists have the potential to be a best-in-class drug with a key differentiated safety and efficacy profile from other FXR agonists in development.